Spyre Therapeutics, Inc. 8-K

What Happened

• Spyre Therapeutics, Inc. filed an 8-K on June 1, 2026 reporting that on May 29, 2026 it entered into a First Amendment to the Amended and Restated IL-23 (SPY003) License Agreement with Paragon Therapeutics, Inc. (the original license dated February 24, 2025). The Amendment expands the defined "Field" from inflammatory bowel disease (IBD) to include all therapeutic, prophylactic, palliative and diagnostic uses, subject to specified dosing timing restrictions.

Key Details

• Amendment date: May 29, 2026; original SPY003 License Agreement dated February 24, 2025.
• Field expansion: SPY003's licensed uses broadened from only IBD to all therapeutic, prophylactic, palliative and diagnostic uses.
• Dosing restrictions: No dosing of a human patient in a clinical trial of SPY003 for a non-IBD indication as part of a combination until June 1, 2028, and as a monotherapy until June 1, 2030 (the "Monotherapy Dosing Restriction").
• Change-of-control/material transaction clause: If Spyre (or a Paragon licensee) completes a material transaction (including a change of control), remaining restrictions outside the initial Field definition will remain only until June 1, 2028 and then terminate.
• No financial terms were disclosed in the 8-K; the full Amendment is filed as Exhibit 10.1.

Why It Matters

• The Amendment legally broadens SPY003’s potential indications, increasing Spyre’s long-term addressable market and strategic flexibility for commercial and diagnostic uses.
• However, the dosing restrictions delay the company’s ability to run clinical trials in non-IBD indications (combination trials until 2028; monotherapy until 2030), which limits near-term clinical development and potential near-term value capture from expanded uses.
• The material-transaction clause means a sale, merger or other change of control could accelerate lifting of some restrictions, which may affect deal value or strategic options for investors.
• No monetary consideration or licensing fees were reported, so financial impact on Spyre’s balance sheet or revenue prospects is not specified in the filing.